熱門資訊> 正文
默克完成对Cidara Therapeutics的现金要约收购
2026-01-07 20:28
- Merck (MRK) has finished its cash tender offer for all outstanding shares of Cidara Therapeutics (CDTX) at a price of $221.50 per Cidara share.
- The deal, announced in November, has a value of $9.2B.
- Merck said after the completion of the merger, it will result in a charge that will increase 2026 research and development expenses by ~$9B or ~$3.65 per share, included in GAAP and non-GAAP results. Also, GAAP and non-GAAP EPS are expected to take a $0.30 per share hit in the first year due to costs associated with advancing CD388 and financing.
- CD388 is an antiviral in phase 3 to prevent influenza infection in individuals at higher risk of influenza complications.
More on Merck
- Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
- Merck: Framework For Success
- Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis
- U.S. measles cases climb to the highest level in over three decades
- Medicare pilot programs aim to reduce prescription drug spend
推薦文章
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
一周IPO | 賺錢效應持續火熱！年內24只上市新股「0」破發；「圖模融合第一股」海致科技首日飆漲逾242%
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
